利用基因组学、分子生物标志物和人工智能实现原发性肝癌治疗的范式转变。
A Paradigm Shift in Primary Liver Cancer Therapy Utilizing Genomics, Molecular Biomarkers, and Artificial Intelligence.
作者信息
Moroney James, Trivella Juan, George Ben, White Sarah B
机构信息
Division of Vascular and Interventional Radiology, Department of Radiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Division of Gastroenterology and Hepatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
出版信息
Cancers (Basel). 2023 May 17;15(10):2791. doi: 10.3390/cancers15102791.
Primary liver cancer is the sixth most common cancer worldwide and the third leading cause of cancer-related death. Conventional therapies offer limited survival benefit despite improvements in locoregional liver-directed therapies, which highlights the underlying complexity of liver cancers. This review explores the latest research in primary liver cancer therapies, focusing on developments in genomics, molecular biomarkers, and artificial intelligence. Attention is also given to ongoing research and future directions of immunotherapy and locoregional therapies of primary liver cancers.
原发性肝癌是全球第六大常见癌症，也是癌症相关死亡的第三大主要原因。尽管局部肝脏定向治疗有所改进，但传统疗法带来的生存获益有限，这凸显了肝癌潜在的复杂性。本综述探讨了原发性肝癌治疗的最新研究，重点关注基因组学、分子生物标志物和人工智能的发展。同时也关注原发性肝癌免疫治疗和局部治疗的当前研究及未来方向。
Zotero 插件